Roche’s Ocrevus, Novartis’ Kesimpta set to lead CNS market to strongest growth in over a decade: report
The global market for central nervous system therapies is on track to log its highest sales numbers since 2013, revitalized in large part by a wave of successful multiple sclerosis meds, according to a new report.
